LISTING OF THE CLAIMS

No claims are amended herein. The claims are provided below for the Examiner's convenience.

1. - 30. (Canceled)

31. *(Previously presented)* A pharmaceutical composition formulated for human administration and effective in treating a neoplastic disease or eliciting an anti-tumor immunological response, comprising:

a) a human cell expressing a cytokine from a recombinant polynucleotide; and

b) a pharmaceutical excipient;

wherein the cytokine is stably associated in the cell outer membrane, and

wherein the cell has been inactivated to prevent proliferation.

32. *(Previously presented)* The composition of claim 31, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

33. *(Previously added)* The composition of claim 31, wherein the cell is a cancer cell.

34. *(Previously presented)* The composition of claim 31, wherein the cell is from a tumor of the same tissue type as a tumor in the human.

35. *(Previously presented)* The composition of claim 34, wherein the tumor is an ovarian cancer or a brain cancer.

36. *(Previously presented)* The composition of claim 31, wherein the cell is allogeneic to the human.

37. *(Previously presented)* The composition of claim 31, wherein the cell is histocompatibly identical to the ~~subject~~ human.

38. *(Previously presented)* The composition of claim 31, further comprising a tumor-associated antigen, wherein the combination of the cytokine and the tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.

39. *(Previously presented)* The composition of claim 38, wherein the tumor-associated antigen is obtained from a cell autologous to the human.

40. *(Previously added)* The composition of claim 38, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.

41. *(Previously presented)* The composition of claim 38, comprising a combination of:

a) the cell expressing the membrane-associated cytokine; and

b) a tumor cell autologous to the human;

wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.

42. *(Previously presented)* The composition of claim 41, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the human.

43. *(Previously added)* The composition of claim 41, wherein the tumor cell is a glioma, a glioblastoma, a gliosarcoma, an astrocytoma, or an ovarian cancer cell.

44. *(Previously presented)* The composition of claim 41, wherein the tumor cell has been inactivated by irradiation.

45. *(Previously presented)* The composition of claim 31, wherein the cell expressing the membrane-associated cytokine has been inactivated by irradiation.

46. *(Previously added)* The composition of claim 31, wherein the cell produces a secreted cytokine in addition to the cytokine stably associated in the outer membrane.

47. *(Previously added)* The composition of claim 31, wherein a majority of the cytokine produced by the cell is present on the outer membrane of the cell.

48. *(Previously presented)* The composition of claim 38, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

49. *(Previously presented)* A composition comprising a tumor associated antigen and a population of cells expressing a transmembrane cytokine ,

wherein the cells have been inactivated to prevent proliferation, and

wherein the composition is effective in stimulating an immune response to the tumor associated antigen.

50. *(Previously presented)* A unit dose of the composition according to claim 31, wherein the number of cells in the composition is at least about 5×10^6 but not more than about 2×10^8.

51. *(Canceled)*

52. *(Previously added)* The composition of claim 31, wherein the cytokine naturally occurs as a membrane cytokine.

53. *(Previously added)* The composition of claim 31, wherein the cytokine is a fusion protein comprising a heterologous transmembrane region.

54. *(Previously added)* The composition of claim 31, wherein the cell has been transduced with a retroviral expression vector, or is the progeny of such a cell.

55. *(Previously added)* A method for producing the composition of claim 31, comprising transducing the cell with an expression vector encoding the membrane-associated cytokine.

56. *(Previously added)* The method of claim 55, wherein the expression vector is a retroviral vector.

57. *(Previously presented)* The method of claim 55, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

58. *(Previously added)* The method of claim 55, wherein the cytokine is expressed under control of a cytomegalovirus (CMV) promoter.

59. *(Previously presented)* The method of claim 55, wherein the cell is from a cancer of the same tissue type as a tumor in the human.

60. *(Previously presented)* The method of claim 55, wherein the cell is allogeneic to the human.

61. *(Previously presented)* The method of claim 55, wherein the cell is histocompatibly identical to the human.

62. *(Previously added)* A method for producing the composition of claim 38, comprising transducing a cell with an expression vector encoding the membrane-associated cytokine, and providing the transduced cell in combination with the tumor-associated antigen.

63. *(Previously presented)* The method of claim 55, further comprising inactivating the cell to prevent proliferation.

64. *(Previously presented)* The method of claim 55, further comprising irradiating the cell.

65. *(Previously presented)* The composition of claim 31, wherein the cytokine is IL-4.

66. *(Previously presented)* The composition of claim 31, wherein the cytokine is GM-CSF.

67. *(Previously presented)* The composition of claim 31, wherein the cytokine is M-CSF.

68. *(Previously presented)* A pharmaceutical composition effective in treating a neoplastic disease or eliciting an anti-tumor immunological response, comprising:

a) a human cell expressing a cytokine from a recombinant polynucleotide; and

b) a pharmaceutical excipient;

wherein the cytokine is stably associated in the cell outer membrane, and

wherein the composition has been formulated for administration to an allogeneic human subject.

69. *(Previously presented)* The composition of claim 68, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF-α, and M-CSF.

70. *(Previously presented)* The composition of claim 68, wherein the cell is a cancer cell.

71. *(Previously presented)* The composition of claim 68, wherein the cell is from a tumor of the same tissue type as a tumor in the human.

72. *(Previously presented)* The composition of claim 68, further comprising a tumor-associated antigen, wherein the combination of the cytokine and the tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.

73. *(Previously presented)* The composition of claim 72, wherein the tumor-associated antigen is obtained from a cell autologous to the human.

74. *(Previously presented)* The composition of claim 72, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.

75. *(Previously presented)* The composition of claim 72, comprising a combination of:

a) the cell expressing the membrane-associated cytokine; and

b) a tumor cell autologous to the human;

wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.

76. *(Previously presented)* The composition of claim 75, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the human.

77. *(Previously presented)* The composition of claim 68, wherein the cell expressing the membrane-associated cytokine has been inactivated by irradiation.

78. *(Previously presented)* A method for producing the composition of claim 68, comprising transducing the cell with an expression vector encoding the membrane-associated cytokine.

79. *(Previously presented)* The method of claim 78, wherein the expression vector is a retroviral vector.

80. *(Previously presented)* The method of claim 78, further comprising inactivating the cell to prevent proliferation.

81. *(Previously presented)* The method of claim 78, further comprising irradiating the cell.